Combination of interleukin-6 and C-reactive protein levels as predictive biomarkers for early diagnosis of community-acquired pneumonia in ICU patients

Background & objective: Pneumonia is a leading cause of morbidity and mortality globally, accounting for 15.2% of deaths in Malaysia in 2023. Community-acquired pneumonia (CAP) poses diagnostic challenges due to the non-specificity of clinical presentations and inconsistencies in imaging interpretation. This study evaluates the diagnostic utility of biomarker interleukin-6 (IL-6), C-reactive protein (CRP) and procalcitonin (PCT), individually and in combination, to improve the diagnosis of CAP in critically ill patients. Methodology: This prospective cohort study was conducted in an intensive care unit. Adult patients admitted with dyspnea and respiratory failure were recruited, with 33 patients classified as CAP by standardized definition, and 42 as non-CAP. Biomarker levels were assessed in both groups, and diagnostic performance was evaluated with optimum cutoff levels. Results: Individually, IL-6, CRP and PCT showed poor diagnostic accuracy (AUC < 0.7). The IL-6 and CRP combination achieved the highest AUC (0.759, sensitivity 78%, specificity 67%). The IL-6 and PCT combination provided the highest sensitivity (91%) and negative predictive value (85%), aiding in ruling out CAP. Conclusion: Combined biomarker evaluation enhances diagnostic accuracy for community-acquired pneumonia, providing a basis for early treatment. These findings warrant further multicenter validation to confirm their clinical applicability in community-acquired pneumonia diagnosis. Abbreviations: CAP: community-acquired pneumonia, CRP: C-reactive protein, IL-6: interleukin-6, PCT: procalcitonin, ICU: intensive care unit Keywords: Biomarker; Interleukin-6; C-Reactive Protein; Procalcitonin; Community-Acquired Pneumonia; Dyspmea; Respiratory Failure Citation: Ramly NF, Wah LK, Nanyan S, Abdul Ghani MR, Ab Rashid I. Combination of interleukin-6 and C-reactive protein levels as predictive biomarkers for early diagnosis of community-acquired pneumonia in ICU patients. Anaesth. pain intensive care 2025;29(2):254-260. DOI: 10.35975/apic.v29i2.2713 Received: May 09, 2024; Reviewed: October 26, 2024; Accepted: January 01, 2025

Authors

Publication Details

Journal
Anaesthesia Pain & Intensive Care
Published
2025-03-27
DOI
https://doi.org/10.35975/apic.v29i2.2713
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combination of interleukin-6 and C-reactive protein levels as predictive biomarkers for early diagnosis of community-acquired pneumonia in ICU patients

Muhamad Rasydan Abdul Ghani, Suhaila Nanyan, Nur Fariza Ramly, Imran Rashid et al.
Anaesthesia Pain & Intensive Care
COVID-19 Clinical Research Studies
article

Combination of interleukin-6 and C-reactive protein levels as predictive biomarkers for early diagnosis of community-acquired pneumonia in ICU patients

Muhamad Rasydan Abdul Ghani, Suhaila Nanyan, Nur Fariza Ramly, Imran Rashid, Lee Kam Wah
article en

Abstract

Background & objective: Pneumonia is a leading cause of morbidity and mortality globally, accounting for 15.2% of deaths in Malaysia in 2023. Community-acquired pneumonia (CAP) poses diagnostic challenges due to the non-specificity of clinical presentations and inconsistencies in imaging interpretation. This study evaluates the diagnostic utility of biomarker interleukin-6 (IL-6), C-reactive protein (CRP) and procalcitonin (PCT), individually and in combination, to improve the diagnosis of CAP in critically ill patients. Methodology: This prospective cohort study was conducted in an intensive care unit. Adult patients admitted with dyspnea and respiratory failure were recruited, with 33 patients classified as CAP by standardized definition, and 42 as non-CAP. Biomarker levels were assessed in both groups, and diagnostic performance was evaluated with optimum cutoff levels. Results: Individually, IL-6, CRP and PCT showed poor diagnostic accuracy (AUC < 0.7). The IL-6 and CRP combination achieved the highest AUC (0.759, sensitivity 78%, specificity 67%). The IL-6 and PCT combination provided the highest sensitivity (91%) and negative predictive value (85%), aiding in ruling out CAP. Conclusion: Combined biomarker evaluation enhances diagnostic accuracy for community-acquired pneumonia, providing a basis for early treatment. These findings warrant further multicenter validation to confirm their clinical applicability in community-acquired pneumonia diagnosis. Abbreviations: CAP: community-acquired pneumonia, CRP: C-reactive protein, IL-6: interleukin-6, PCT: procalcitonin, ICU: intensive care unit Keywords: Biomarker; Interleukin-6; C-Reactive Protein; Procalcitonin; Community-Acquired Pneumonia; Dyspmea; Respiratory Failure Citation: Ramly NF, Wah LK, Nanyan S, Abdul Ghani MR, Ab Rashid I. Combination of interleukin-6 and C-reactive protein levels as predictive biomarkers for early diagnosis of community-acquired pneumonia in ICU patients. Anaesth. pain intensive care 2025;29(2):254-260. DOI: 10.35975/apic.v29i2.2713 Received: May 09, 2024; Reviewed: October 26, 2024; Accepted: January 01, 2025

Anaesthesia Pain & Intensive CareVol. 29(2)
Openalex Percentile: Top 82%
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.